Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576418 | 0.98 | KDM4E (0.51) | KDM4ETSHRHPGDHSD17B10ALDH1A1 | |
| SCHEMBL27978196 | 0.83 | CREBBP (0.51) | KDM4ETSHRHPGDHSD17B10ALDH1A1 | |
| SCHEMBL2851306 | 0.81 | ALDH1A1 (0.55) | KDM4ETSHRALDH1A1MAPTLMNA | |
| SCHEMBL16867095 | 0.76 | ALDH1A1 (0.48) | KDM4ETSHRHSD17B10ALDH1A1MAPT | |
| Bromide SCHEMBL7918168 | 0.76 | PPARG (0.44) | TSHRHPGDHSD17B10ALDH1A1MAPT | |
| Bromide SCHEMBL11028063 | 0.76 | POLB (0.45) | KDM4ETSHRHSD17B10ALDH1A1MAPT | |
| SCHEMBL31528647 | 0.76 | FPR2 (0.45) | KDM4EALDH1A1LMNAGSK3AGSK3B | |
| Hydrochloric Acid SCHEMBL5450987 | 0.76 | BCHE (0.45) | KDM4ETSHRHPGDHSD17B10ALDH1A1 | |
| SCHEMBL2237187 | 0.76 | ALDH1A1 (0.50) | KDM4ETSHRALDH1A1MAPTLMNA | |
| SCHEMBL3719707 | 0.74 | KDM4E (0.53) | KDM4ETSHRHPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074121-B1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-11-30 | — | — | EP | disclosed |
| US-8193214-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-05 | — | — | US | disclosed |
| US-20100029637-A1 | Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-2074121-A1 | CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008045688-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029637-A1 | Chymase Inhibitors | CMA1, CPA3, SERPINB1 | KDM4E 3782/4885TSHR 3397/4885HPGD 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.